Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

被引:9
|
作者
Jia, Yaxun [1 ]
Wang, Min [1 ]
Sang, Xiaolin [1 ]
Liu, Pixu [2 ]
Gao, Jingchun [3 ]
Jiang, Kui [4 ]
Cheng, Hailing [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dalian Key Lab Mol Targeted Canc Therapy, Canc Inst, Dalian, Peoples R China
[2] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China
[3] Dalian Med Univ, Hosp 1, Dept Obstet & Gynecol, Dalian, Peoples R China
[4] Dalian Med Univ, Hosp 2, Dept Med Oncol, Dalian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
BMN; 673; high-grade serous ovarian cancer; PARP inhibitor; phenethyl isothiocyanate; reactive oxygen species; OXIDATIVE STRESS; ORGANIC ISOTHIOCYANATES; THERAPY; RESISTANCE; COMBINATION; ONCOGENE; OLAPARIB;
D O I
10.3389/fonc.2021.812264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders may eventually become resistant. Therefore, the development of novel effective combinatorial strategies to treat HGSOC is urgently needed. Here, we report that H2O2-induced oxidative stress sensitized HGSOC cells to PARPi BMN 673. Furthermore, Phenethyl isothiocyanate (PEITC) as a ROS-inducing agent significantly enhanced the cytotoxic effects of BMN 673. Mechanistically, combined use of PEITC and BMN 673 resulted in ROS overproduction and accumulation, enhanced DNA damage, G2/M arrest and apoptosis, all of which were significantly reversed by the ROS scavenger N-Acetyl-L-cysteine. We also showed that while PEITC did not further enhance the ability of BMN 673 on PARP1 trapping in HGSOC cells, the therapeutic effects of the PEITC/BMN 673 combination were at least in part dependent on the presence of PARP1. Importantly, the PEITC/BMN 673 combination potently abrogated the growth of HGSOC tumor spheroids and patient-derived organoid models of HGSOC and cervical cancer. Our findings provide a basis for further investigation of the utility of PARPi combination regimen in HGSOC and cervical cancer through ROS-mediated mechanisms.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Novel strategies for targeting high-grade serous ovarian cancer
    Perets, Ruth
    Wyant, Gregory A.
    Ohman, Anders W.
    Setlur, Sunita R.
    Crum, Christopher P.
    Drapkin, Ronny
    Dinulescu, Daniela M.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21
  • [42] Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L.
    Brenton, James D.
    [J]. LANCET ONCOLOGY, 2011, 12 (12): : 1169 - 1174
  • [43] Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
    Freimund, Alison E.
    Beach, Jessica A.
    Christie, Elizabeth L.
    Bowtell, David D. L.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 983 - +
  • [44] Tumor immunogenicity status in high-grade serous ovarian cancer
    Berry, Laurel
    Kelly, Michael
    Miller, Lance
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S319 - S319
  • [45] Describing intratumoural heterogeneity in high-grade serous ovarian cancer
    Nixon, K.
    Wulandari, R.
    Curry, E.
    Rama, N.
    Bowtell, D.
    Cunnea, P.
    Fotopoulou, C.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 126 : 87 - 88
  • [46] Defining the Molecular Footsteps of High-Grade Serous Ovarian Cancer
    Nagendra, P.
    Lombard, J.
    Jamaluddin, F.
    Tanwar, P.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 26 - 26
  • [47] Principles of dormancy evident in high-grade serous ovarian cancer
    Shepherd, Trevor G.
    Dick, Frederick A.
    [J]. CELL DIVISION, 2022, 17 (01)
  • [48] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1547 - 1547
  • [49] SHOULD AROMATASE INHIBITORS BE USED AS MAINTENANCE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENTS?
    Heinzelmann-Schwarz, V.
    Knipprath-Meszaros, A. M.
    Francis, J.
    Stadlmann, S.
    Vigo, F.
    Schoetzau, A.
    Singer, G.
    Vetter, M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 307 - 307
  • [50] Isolation and Characterization of Cancer Stem Cells from High-Grade Serous Ovarian Carcinomas
    He, Qi-zhi
    Luo, Xue-zhen
    Wang, Kai
    Zhou, Qian
    Ao, Hong
    Yang, Yan
    Li, Shu-xia
    Li, Ying
    Zhu, Hui-ting
    Duan, Tony
    [J]. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2014, 33 (01) : 173 - 184